The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
A 24-Week Treatment Strategy With Pegylated Interferon/Ribavirin in HIV/Hepatitis C Virus Genotype 3-Coinfected Patients Who Achieved a Rapid Virologic Response Results in a High Sustained Virologic Response Rate
Rivero-Juarez A, López-Cortés LF, Camacho A, Mira JA, Téllez F, Marquez M, Merino D, Pineda JA, Rivero A; for the Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR), part of the Sociedad Andaluza de Enfermedades Infecciosas. Clin Infect Dis. 2013 Oct 21. [Epub ahead of print]
Source
Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba, Hospital Universitario Reina Sofia de Cordoba.
Abstract
We designed a study to evaluate the efficacy of a 24-week treatment strategy in HIV/hepatitis C virus (HCV) genotype 3-coinfected patients achieving rapid virologic response for a first HCV treatment with pegylated interferon plus ribavirin (peg-IFN/RBV). Our results suggest that a shorter course of peg-IFN/RBV therapy may be sufficient in this population.